334 related articles for article (PubMed ID: 37834408)
1. Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma Treatment.
Singh S; Barik D; Lawrie K; Mohapatra I; Prasad S; Naqvi AR; Singh A; Singh G
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834408
[TBL] [Abstract][Full Text] [Related]
2. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.
Sami A; Karsy M
Tumour Biol; 2013 Aug; 34(4):1991-2002. PubMed ID: 23625692
[TBL] [Abstract][Full Text] [Related]
5. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN.
Park S; Zhao D; Hatanpaa KJ; Mickey BE; Saha D; Boothman DA; Story MD; Wong ET; Burma S; Georgescu MM; Rangnekar VM; Chauncey SS; Habib AA
Cancer Res; 2009 May; 69(10):4107-11. PubMed ID: 19435890
[TBL] [Abstract][Full Text] [Related]
6. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE; Jücker M
Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
[TBL] [Abstract][Full Text] [Related]
7. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia enhances the migration and invasion of human glioblastoma U87 cells through PI3K/Akt/mTOR/HIF-1α pathway.
Huang W; Ding X; Ye H; Wang J; Shao J; Huang T
Neuroreport; 2018 Dec; 29(18):1578-1585. PubMed ID: 30371540
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting 4EBP1 in Glioblastoma.
Fan QW; Nicolaides TP; Weiss WA
Clin Cancer Res; 2018 Jan; 24(1):14-21. PubMed ID: 28696243
[TBL] [Abstract][Full Text] [Related]
10. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
11. Voxtalisib and low intensity pulsed ultrasound combinatorial effect on glioblastoma multiforme cancer stem cells via PI3K/AKT/mTOR.
Tutak I; Ozdil B; Uysal A
Pathol Res Pract; 2022 Nov; 239():154145. PubMed ID: 36240647
[TBL] [Abstract][Full Text] [Related]
12. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma.
Barzegar Behrooz A; Talaie Z; Jusheghani F; Łos MJ; Klonisch T; Ghavami S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163279
[TBL] [Abstract][Full Text] [Related]
13. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
Yu L; Wei J; Liu P
Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
[TBL] [Abstract][Full Text] [Related]
14. Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
Oppermann H; Faust H; Yamanishi U; Meixensberger J; Gaunitz F
PLoS One; 2019; 14(6):e0218972. PubMed ID: 31247000
[TBL] [Abstract][Full Text] [Related]
15. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
16. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.
Moench R; Grimmig T; Kannen V; Tripathi S; Faber M; Moll EM; Chandraker A; Lissner R; Germer CT; Waaga-Gasser AM; Gasser M
Oncotarget; 2016 Oct; 7(42):68749-68767. PubMed ID: 27626684
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
18. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
[TBL] [Abstract][Full Text] [Related]
19. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma.
Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD
Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088
[TBL] [Abstract][Full Text] [Related]
20. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
